

6-3-2021

Erratum: Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders (The American Journal of Human Genetics (2020) 106(3) (356–370), (S0002929720300197), (10.1016/j.ajhg.2020.01.019))

Erfan Aref-Eshghi

Jennifer Kerkhof

Victor P. Pedro

Groupe DI France

Mouna Barat-Houari

See next page for additional authors

Follow this and additional works at: <https://ir.lib.uwo.ca/paedpub>

Citation of this paper:

Aref-Eshghi, Erfan; Kerkhof, Jennifer; Pedro, Victor P.; France, Groupe DI; Barat-Houari, Mouna; Ruiz-Pallares, Nathalie; Andrau, Jean Christophe; Lacombe, Didier; Van-Gils, Julien; Fergelot, Patricia; Dubourg, Christéle; Cormier-Daire, Valerie; Rondeau, Sophie; Lecoquierre, François; Saugier-veber, Pascale; Nicolas, Gaël; Lesca, Gaetan; Chatron, Nicolas; Sanlaville, Damien; Vitobello, Antonio; Faivre, Laurence; Thauvin-Robinet, Christel; Laumonnier, Frederic; Raynaud, Martine; Alders, Mariëlle; Mannens, Marcel; Henneman, Peter; Hennekam, Raoul C.; and Velasco, Guillaume, "Erratum: Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders (The American Journal of Human Genetics (2020) 106(3) (356–370), (S0002929720300197), (10.1016/j.ajhg.2020.01.019))" (2021). *Paediatrics Publications*. 734.
<https://ir.lib.uwo.ca/paedpub/734>

Authors

Erfan Aref-Eshghi, Jennifer Kerkhof, Victor P. Pedro, Groupe DI France, Mouna Barat-Houari, Nathalie Ruiz-Pallares, Jean Christophe Andrau, Didier Lacombe, Julien Van-Gils, Patricia Fergelot, Christéle Dubourg, Valerie Cormier-Daire, Sophie Rondeau, François Lecoquierre, Pascale Saugier-Veber, Gaël Nicolas, Gaetan Lesca, Nicolas Chatron, Damien Sanlaville, Antonio Vitobello, Laurence Faivre, Christel Thauvin-Robinet, Frederic Laumonnier, Martine Raynaud, Mariëlle Alders, Marcel Mannens, Peter Henneman, Raoul C. Hennekam, and Guillaume Velasco

Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders

Erfan Aref-Eshghi, Jennifer Kerkhof, Victor P. Pedro, Groupe DI France, Mouna Barat-Houari, Nathalie Ruiz-Pallares, Jean-Christophe Andrau, Didier Lacombe, Julien Van-Gils, Patricia Fergelot, Christèle Dubourg, Valerie Cormier-Daire, Sophie Rondeau, François Lecoquierre, Pascale Saugier-Veber, Gaël Nicolas, Gaetan Lesca, Nicolas Chatron, Damien Sanlaville, Antonio Vitobello, Laurence Faivre, Christel Thauvin-Robinet, Frederic Laumonnier, Martine Raynaud, Mariëlle Alders, Marcel Mannens, Peter Henneman, Raoul C. Hennekam, Guillaume Velasco, Claire Francastel, Damien Ulveling, Andrea Ciolfi, Simone Pizzi, Marco Tartaglia, Solveig Heide, Delphine Héron, Cyril Mignot, Boris Keren, Sandra Whalen, Alexandra Afenjar, Thierry Bienvenu, Philippe M. Campeau, Justine Rousseau, Michael A. Levy, Lauren Brick, Mariya Kozenko, Tugce B. Balci, Victoria Mok Siu, Alan Stuart, Mike Kadour, Jennifer Masters, Kyoko Takano, Tjitske Kleefstra, Nicole de Leeuw, Michael Field, Marie Shaw, Jozef Gecz, Peter J. Ainsworth, Hanxin Lin, David I. Rodenhiser, Michael J. Friez, Matt Tedder, Jennifer A. Lee, Barbara R. DuPont, Roger E. Stevenson, Steven A. Skinner, Charles E. Schwartz, David Genevieve, and Bekim Sadikovic*

(The American Journal of Human Genetics 106, 356–370; March 5, 2020)

In the version of this paper originally published, the underlying cause for Hunter McAlpine syndrome was incorrectly described in Table 1. The relevant description has been changed to read “Chr5q35-qter duplication involving *NSD1*” in the updated Table 1 reflected here. The authors apologize for this error.

*Correspondence: Bekim.Sadikovic@lhsc.on.ca

<https://doi.org/10.1016/j.ajhg.2021.04.022>.

© 2021 American Society of Human Genetics.



Table 1. Description of the Study Cohort

Syndrome/Episignature	Abbreviation	Underlying Genes	Phenotype MIM Number	Training Cohort	Testing Cohort	Episignature Detected?
ADNP syndrome—5' and 3' terminal ends	ADNP_T	ADNP (outside c.2000-2340)	615873	14	5	yes
ADNP syndrome—central	ADNP_C	ADNP (c.2000-2340)	615873	10	3	yes
alpha-thalassemia mental retardation syndrome	ATRX	ATRX	301040	13	5	yes
autism, susceptibility to, 18	AUTS18 ^a	CHD8	615032	5	0	yes
BAFopathies: Coffin-Siris 1–4 (CSS1–4) and Nicolaides-Baraitser (NCBRS) syndromes	BAFopathy ^a	ARID1A ^a , ARID1B, SMARCB1, SMARCA4, SMARCA2	614607, 135900, 614609, 614608, 601358	50	19	yes
Börjeson-Forssman-Lehmann syndrome	BFLS ^a	PHF6	301900	4	0	yes
cerebellar ataxia, deafness, and narcolepsy, autosomal dominant	ADCADN	DNMT1	604121	5	0	yes
CHARGE syndrome	CHARGE	CHD7	214800	45	15	yes
Chr7q11.23 duplication syndrome	Dup7	Chr7q11.23 duplication	609757	8	2	yes
mental retardation, X-linked, syndromic, Claes-Jensen type (Claes-Jensen syndrome)	CJS	KDM5C	300534	26	8	yes
Cornelia de Lange syndrome 1–4	CdLS	NIPBL, RAD21, SMC3, SMC1A	122470, 614701, 610759, 300590	31	10	yes
Down syndrome	Down	Chr21 trisomy	190685	29	10	yes
epileptic encephalopathy, childhood-onset	EEOC ^a	CHD2	615369	5	0	yes
Floating-Harbor syndrome	FHS	SRCAP	136140	15	5	yes
genitopatellar syndrome	GTPTS	KAT6B	606170	5	0	yes
Hunter McAlpine syndrome	HMA ^a	Chr5q35-qter duplication involving NSD1	601379	4	0	yes
immunodeficiency-centromeric instability-facial anomalies syndrome 1	ICF1	DNMT3B	242860	8	0	yes
immunodeficiency-centromeric instability-facial anomalies syndrome 2–4	ICF2_3_4	CDCA7, ZBTB24, HELLS	614069, 616910, 616911	7	0	yes
Kabuki syndrome 1 and 2	Kabuki ^a	KMT2D, KDM6A ^a	147920, 300867	66	21	yes
Kleefstra syndrome 1	Kleefstra1 ^a	EHMT1	610253	15	5	yes
Koolen de Vreis syndrome	KDVS ^a	KANSL1	610443	6	0	yes
mental retardation, autosomal dominant 51	MRD51 ^a	KMT5B	617788	5	0	yes
mental retardation, X-linked 93	MRX93 ^a	BRWD3	300659	5	0	yes
mental retardation, X-linked 97	MRX97 ^a	ZNF711	300803	13	4	yes
mental retardation, X-linked syndromic, Nascimento-type	MRXSN ^a	UBE2A	300860	3	0	yes
mental retardation, X-linked, Snyder-Robinson type	MRXSSR ^a	SMS	309583	8	2	yes
Rahman syndrome	RMNS ^a	HIST1H1E	617537	6	0	yes
Rubinstein-Taybi syndrome 1 and 2	RSTS ^a	CREBBP, EP300	180849, 613684	30	9	yes

(Continued on next page)

Table 1. Continued

Syndrome/Episignature	Abbreviation	Underlying Genes	Phenotype MIM Number	Training Cohort	Testing Cohort	Episignature Detected?
SBBYSS syndrome	SBBYSS ^a	<i>KAT6B</i>	603736	7	0	yes
SETD1B-related syndrome	SETD1B ^a	<i>SETD1B</i>	N/A	8	0	yes
Sotos syndrome	Sotos	<i>NSD1</i>	117550	47	15	yes
Tatton-Brown-Rahman syndrome	TBR ^a	<i>DNMT3A</i>	615879	10	4	yes
Wiedemann-Steiner syndrome	WDSTS ^a	<i>KMT2A</i>	605130	12	4	yes
Williams syndrome	Williams	Chr7q11.23 deletion	194050	15	6	yes
Cornelia de Lange syndrome 5 (females only)	CdLS5	<i>HDAC8</i>	300882	8	N/A	no
FG syndrome 1	FG1 ^{a,b}	<i>MED12</i>	305450	9	N/A	no
Glass syndrome	Glass ^{a,b}	<i>SATB2</i>	612313	9	N/A	no
KMT2C-related syndrome ^c	KMT2C ^{a,b,c}	<i>KMT2C</i>	617768	4	N/A	no
neurodevelopmental disorder with coarse facies and mild distal skeletal abnormalities	NEDCFSA ^{a,b}	<i>KDM6B</i>	618505	5	N/A	no
Rett syndrome	Rett	<i>MECP2</i>	312750	36	N/A	no
Siderius-type X-linked syndromic mental retardation	MRXSSD ^{a,b}	<i>PHF8</i>	300263	9	N/A	no
Smith-Magenis syndrome	SMS ^{a,b}	<i>RAI1</i>	309583	15	N/A	no

^aIndicates that these disorders (or some of their subtypes) were not evaluated in previous studies.

^bIndicates cohorts with no evidence of a reproducible episignature; this is potentially due to small sample size. A possibility of an episignature is not completely ruled out, and reanalysis using larger sample sizes is warranted.

^cThe OMIM database, at the time of this study, has indicated that subjects with *KMT2C* mutations may be said to have “Kleefstra 2” syndrome. The DNA methylation signature found in Kleefstra 1 (caused by *EHMT1*), however, is completely absent in these subjects. It is acknowledged that these subjects have a distinct phenotype from Kleefstra syndrome and a name change is currently in process with OMIM. The numbers in the testing and training cohort columns indicate the sample counts available for each condition in each category. For cohorts with negative findings in the initial assessment, we did not further split the data into testing and training, and thus, the values in the testing column are indicated with N/A (not applicable).